SVWAG
BMRN icon

Sound View Wealth Advisors Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sound View Wealth Advisors Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Buy
7,516
+206
+3% +$12K 0.03% 295
2025
Q4 		$434K Buy
+7,310
New +$398K 0.03% 293

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sound View Wealth Advisors Group's BMRN Position: Q1 2026 in Review

Sound View Wealth Advisors Group increased its BioMarin Pharmaceuticals (BMRN) stake by 2.8% in Q1 2026, buying an estimated $12K and bringing the position to 7,516 shares worth $425K. The position accounts for 0.03% of the portfolio, ranked #295.

Sound View Wealth Advisors Group first reported a position in BMRN in Q4 2025 and has held it in 2 quarters since. The position peaked at $434K in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Sound View Wealth Advisors Group held 7,516 shares of BioMarin Pharmaceuticals worth $425K as of Q1 2026.
  • Sound View Wealth Advisors Group bought 206 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $12K.
  • BioMarin Pharmaceuticals made up 0.03% of Sound View Wealth Advisors Group's portfolio in Q1 2026, its #295 holding.
  • Sound View Wealth Advisors Group first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Sound View Wealth Advisors Group's BioMarin Pharmaceuticals position peaked at $434K in Q4 2025.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Sound View Wealth Advisors Group's 13F filing for Q1 2026, filed 6 May 2026.